Glofitamab Cost-Effectiveness: Conditional Reim...

By HEOR Staff Writer

February 17, 2026

Glofitamab Cost-Effectiveness in R/R DLBCL Reimbursement Glofitamab cost-effectiveness analysis by Zorginstituut Nederland supports conditional inclusion of glofitamab (Columvi...
NICE Endorses Pegzilarginase for Treating Arginase Deficiency
Advancing Cancer Screening in Slovenia: A Pathway to Equitable Care
Robotic Surgery Portugal: A Landmark Achievement at ULS Viseu Dão-Lafões
Strategic Vision and Infarmed 2026 Priorities for Regulatory Reform
AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion i...
Enhancing Early-Stage Cancer Treatment: Overcoming Barriers for Better Outcomes
European Pharma Competitiveness: A Cornerstone for EU Economic Resilience
National HealthTech Access: Transforming NHS Adoption and Equity
Tislelizumab NSCLC Inclusion Recommended for Dutch Health Package
Healthcare Innovation Trends Shaping the Future: Insights from the J.P. Morga...
Novo Nordisk Growth Projections: Insights on 2025 Performance and 2026 Outlook
AI Healthcare Costs: Navigating Financial Hurdles in Technology Integration